ACR Convergence 2023 Highlights: Obinutuzumab Efficacy and Tolerance in Patients with Autoimmune Diseases Immunized Against Rituximab

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

0:00

Stream Type LIVE

Remaining Time -0:00

0.5x
0.75x
1x, selected
1.25x
1.5x
1.75x
2x

Chapters

descriptions off, selected

captions settings, opens captions settings dialog
captions off, selected

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorTransparency

BackgroundColorTransparency

WindowColorTransparency

Font Size

Text Edge Style

Font Family

End of dialog window.

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

ACR Convergence 2023 Highlights: Obinutuzumab Efficacy and Tolerance in Patients with Autoimmune Diseases Immunized Against Rituximab

By Highlights from ACR Convergence 2023 FEATURING Samuel Bitoun

0 views

November 28, 2023

The above content is not sponsored by, nor part of, the American College of Rheumatology. ...
read more ↘

View American College of Rheumatology educational opportunities here https://rheumatology.org/events-programs
↖ read less

Comments 0

Expert Perspectives on CSU

Feat. T. Murphy

Shared Voices in the CSU Community

Feat. S. Gawchik

USSONAR Rheumatology Ultrasound Case Series: A Case of Salivary Glan…

Feat. H. Yang